WEST CONSHOHOCKEN, Pa. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We are pleased with the substantial progress the Company made in 2020, particularly in light of the
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH : Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™ , AASLD Product Theater on Friday , November 13 , 2020 , at 4:30 PM ET . In the 100 mg open label arm of MAESTRO-NAFLD : At week
CONSHOHOCKEN, Pa. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments.